Syntekabio Inc. Selected for Ministère de SMEs 2024 Industry-Academia-Research Collabo R&D Program... Commencing AI-Based Psoriasis Treatment Development
▶ Syntekabio-Sogang University, RudaCure-Inje University... Synergy expected through multidisciplinary collaboration
▶ Gouvernement R&D support to foster national strategic technologies and regional strategic industries
Syntekabio Inc. (PDG Jongsun Jeong) a annoncé avoir été sélectionnée for the '2024 Industry-Academia-Research Collabo R&D' program (preliminary research) supported by the Ministère de SMEs and Startups and signed the accord on the 12th.
This research vise à discover candidat-médicament innovants for psoriasis treatment and will demonstrate the efficiency of an AI-based plateforme de développement de médicaments.
Syntekabio has formed an industrie-academia-research consortium with RudaCure Inc., Sogang University, and Inje University to jointly conduct this research. The research topic is 'Development of selective modulators for psoriasis target proteins using an AI plateforme de médicaments,' with a total research period from May 2025 to May 2026.
Syntekabio's AI plateforme de développement de médicaments 'STB' was used for computer-based target protein analysis and composé candidat discovery. RudaCure's TRPV1 modulation technology expertise provides specialized knowledge in skin disease-related canal ionique research. Sogang University is responsible for compound synthesis and optimization, while Inje University handles in-vitro and in-vivo efficacy evaluation of composé candidats.
CEO Jongsun Jeong of Syntekabio a déclaré : "Through AI-based développement de médicaments, we will pioneer new possibilities in the psoriasis treatment market. Through collaboration with excellent partners like RudaCure, Sogang University, and Inje University, we expect remarquable results."